These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23706613)

  • 21. Successful translation of pharmacogenetics into the clinic: the abacavir example.
    Phillips E; Mallal S
    Mol Diagn Ther; 2009; 13(1):1-9. PubMed ID: 19351209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.
    Rodríguez-Nóvoa S; Cuenca L; Morello J; Córdoba M; Blanco F; Jiménez-Nácher I; Soriano V
    J Antimicrob Chemother; 2010 Aug; 65(8):1567-9. PubMed ID: 20534626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The frequency of HLA-B(∗)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica.
    Arrieta-Bolaños E; Madrigal JA; Marsh SG; Shaw BE; Salazar-Sánchez L
    Hum Immunol; 2014 Nov; 75(11):1092-6. PubMed ID: 25286002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abacavir hypersensitivity reaction.
    AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
    [No Abstract]   [Full Text] [Related]  

  • 26. Current trends in screening across ethnicities for hypersensitivity to abacavir.
    Rodriguez-Nóvoa S; Soriano V
    Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine profiling in abacavir hypersensitivity patients.
    Almeida CA; Martin AM; Nolan D; Lucas A; Cameron PU; James I; Phillips E; Mallal S
    Antivir Ther; 2008; 13(2):281-8. PubMed ID: 18505179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK.
    Sadiq ST; Pakianathan M
    Sex Transm Infect; 2007 Jun; 83(3):181-2. PubMed ID: 17098765
    [No Abstract]   [Full Text] [Related]  

  • 29. Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results.
    Redwood AJ; Rwandamuriye F; Chopra A; Leary S; Ram R; McDonnell W; Konvinse K; White K; Pavlos R; Koelle DM; Mallal S; Phillips EJ
    J Allergy Clin Immunol; 2019 Nov; 144(5):1413-1416.e7. PubMed ID: 31574267
    [No Abstract]   [Full Text] [Related]  

  • 30. Avidity determines T-cell reactivity in abacavir hypersensitivity.
    Adam J; Eriksson KK; Schnyder B; Fontana S; Pichler WJ; Yerly D
    Eur J Immunol; 2012 Jul; 42(7):1706-16. PubMed ID: 22585534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions.
    Kapoor S
    AIDS Patient Care STDS; 2008 Oct; 22(10):769. PubMed ID: 18778242
    [No Abstract]   [Full Text] [Related]  

  • 32. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.
    Rauch A; Nolan D; Thurnheer C; Fux CA; Cavassini M; Chave JP; Opravil M; Phillips E; Mallal S; Furrer H;
    Antivir Ther; 2008; 13(8):1019-28. PubMed ID: 19195327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.
    Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774
    [No Abstract]   [Full Text] [Related]  

  • 36. Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
    Hetherington S; Hughes AR; Mosteller M; Shortino D; Baker KL; Spreen W; Lai E; Davies K; Handley A; Dow DJ; Fling ME; Stocum M; Bowman C; Thurmond LM; Roses AD
    Lancet; 2002 Mar; 359(9312):1121-2. PubMed ID: 11943262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.
    Phillips EJ; Sullivan JR; Knowles SR; Shear NH
    AIDS; 2002 Nov; 16(16):2223-5. PubMed ID: 12409746
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug hypersensitivity in HIV.
    Phillips E; Mallal S
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.
    Nieves Calatrava D; Calle-Martín Ode L; Iribarren-Loyarte JA; Rivero-Román A; García-Bujalance L; Pérez-Escolano I; Brosa-Riestra M
    Enferm Infecc Microbiol Clin; 2010 Nov; 28(9):590-5. PubMed ID: 20144493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.